Table 3.
Summary of findings.
| Studies | Participants | Effect estimate | Heterogeneity | ||
|---|---|---|---|---|---|
| ITT analysis | Anatomical success at short-term | 4 | 615 | RR 0.98 [0.94, 1.03]; P = 0.44 | P = 0.09; I2 = 53% |
| Anatomical success at mid-term | 3 | 496 | RR 0.89 [0.84, 0.95]; P = 0.0002 | P = 0.53; I2 = 0% | |
| Available case analysis | Anatomical success at short-term | 4 | 532 | RR 0.98 [0.93, 1.03]; P = 0.46 | P = 0.08; I2 = 56% |
| Anatomical success at mid-term | 3 | 386 | RR 0.89 [0.84, 0.96]; P = 0.001 | P = 0.67; I2 = 0% | |
| Adverse events | Major complication | 4 | 615 | RR 0.33 [0.09, 1.28]; P = 0.11 | P = 0.73; I2 = 0% |
| Phlebitis | 4 | 615 | RR 1.39 [0.67, 2.86]; P = 0.37 | P = 0.58; I2 = 0% |